The Institute for Clinical and Economic Review (ICER) will perform value and effectiveness assessments on several drugs for multiple sclerosis. The drugs include several monoclonal antibody treatments from manufacturers like Biogen, Novartis, and Genentech and some biosimilars for Rituximab. The […]
ICER White Paper – Rare Disease Drug Policy Reform, Drug Access, and Innovation
Despite the advancements in rare disease treatment, patients with many rare diseases still have extremely limited, if any, treatment options. Changes in regulatory approval for rare disease drugs like the Orphan Drug Act have helped to bring new treatments to the clinic, but some worry whether the […]
ICER Will Develop California State Unsupported Price Reports
The California Health Care Foundation (CHCF) has awarded The Institute for Clinical and Economic Review (ICER) a new grant to develop 2 California-specific unsupported price increase reports. In addition, the grant will support the development of a policymaker guide to use comparative effectiveness […]
ICER: Final Evidence Report and Policy Recommendations on Tirzepatide Now Available
The Institute for Clinical and Economic Review (ICER) just released their final evidence report on the diabetes 2 drug terzepatide. ICER found adequate evidence that Eli Lilly’s drug improved symptoms but did not find it had benefits over injectable semaglutide. The institute also determined that […]
ICER Releases Draft Report on Plinabulin and Trilaciclib for Chemo-induced Neutropenia
The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for the novel drugs plinabulin (BeyondSpring Pharmaceuticals) and trilaciclib (Cosela™, G1 Therapeutics). The report assessed the comparative clinical effectiveness and value of the two drugs that are […]
ICER Releases Evidence Report for Type 2 Diabetes Drug Tirzepatide
The Institute for Clinical and Economic Review (ICER) has released their revised evidence report for Eli Lilly’s new type 2 diabetes drug tirzepatide. The drug is intended as an adjunct therapy for metformin and is more effective than injectable semaglutide, another adjunct therapy. A virtual public […]
Final ICER Evidence Report on Tezepelumab for Severe Asthma
A final evidence report for the clinical effectiveness and value of Tezepelumab, a treatment for severe asthma, has been released by the Institute for Clinical and Economic Review (ICER). The report finds that although the evidence isn’t adequate to find advantages over other drugs for severe […]
Gene Therapy for Beta Thalassemia Gene Under ICER Assessment
A gene therapy for beta thalassemia will undergo ICER assessment for comparative clinical effectiveness and value. Betibeglogene autotemcel (Zynteglo/LentiGlobin) from Bluebird Bio will likely receive an FDA decision by mid-2022. ICER has released an outline of its strategy for the assessment. It […]
Upcoming ICER Webinar Will Discuss Barriers to Fair Access
On December 3rd (12 PM), the Institute for Clinical and Economic Review will host a public webinar detailing the findings of their annual assessment of Barriers to Fair Access in major US payers’ prescription drug coverage policies. Presenters include Sara Edmond, Cat Ahmed, Rebecca Kirch, and […]
Panalgo and HealthEconomics.Com Host Webinar on Successful ICER Strategies
Panalgo and HealthEconomics.Com hosted a webinar detailing strategies that lead to successful evaluation by the Institute for Clinical and Economic Review (ICER). President of HealthEconomics.Com Patti Peeples moderated the session, which included important insights from Center for the Evaluation of […]
